Alexa Fluor® 488 Anti-GABA B Receptor 2 antibody [EP2411Y],Abcam,AB309875

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human, Mouse, Rat

Application

Antibody Labelling, IHC-P, Target Binding Affinity, Flow Cyt (Intra)

Conjugate

Alexa Fluor® 488

Platform ID

BAB342813515

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAlexa Fluor® 488 Anti-GABA B Receptor 2 antibody [EP2411Y]
Cat. No.AB309875
HostRabbit
IsotypeIgG
ReactivityHuman, Mouse, Rat
ConjugationAlexa Fluor® 488
ApplicationAntibody Labelling, IHC-P, Target Binding Affinity, Flow Cyt (Intra)
ClonalityMonoclonal
Clone NumberEP2411Y
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2 (PubMed : 15617512, PubMed : 18165688, PubMed : 22660477, PubMed : 24305054, PubMed : 9872316, PubMed : 9872744). Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins (PubMed : 18165688). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase (PubMed : 10075644, PubMed : 10773016, PubMed : 24305054). Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis (PubMed : 10075644, PubMed : 10773016, PubMed : 10906333, PubMed : 9872744). Plays a critical role in the fine-tuning of inhibitory synaptic transmission (PubMed : 22660477, PubMed : 9872744). Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials (PubMed : 10075644, PubMed : 22660477, PubMed : 9872316, PubMed : 9872744). Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception (Probable). See full target information GABBR2

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.